Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TheraCour Cell Therapy (Parkinson's) is a preclinical cell replacement therapy being developed by AllExcel for the treatment of Parkinson's disease. The therapy involves the transplantation of factory-manufactured, HLA-matched dopaminergic cells designed to replace the substantia nigra neurons lost during the progression of the disease. To enhance cell survival and protect against host immune responses, the cells are encapsulated in AllExcel's proprietary TheraCour gel, a micelle-forming, self-assembling polymeric material. This approach aims to provide a curative treatment by restoring dopamine production in the brain while minimizing the need for immunosuppression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TheraCour Cell Therapy (Parkinson's).